The Drug-Induced Respiratory Disease Website and App

Antiviral therapy/agents (direct-acting) against hepatitis C virus

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.b

Pneumonitis (ILD), acute and/or severe (may cause ARDS)

Publications

Wong YJ, Chew SY, Hsiang JC, Thurairajah PH, Kumar R, Teo EK, Gokhale RS, Noor IBM, Tan J

VIEKIRA PAK associated drug-induced interstitial lung disease: Case series with systematic review of literature.

Clinical and molecular hepatology 2019 Jun;25;218-222 — 2019 Jun — 218-222

Omichi K, Akamatsu N, Mori K, Togashi J, Arita J, Kaneko J, Hasegawa K, Sakamoto Y, Kokudo N

Asunaprevir/daclatasvir and sofosbuvir/ledipasvir for recurrent hepatitis C following living donor liver transplantation.

Hepatology research : the official journal of the Japan Society of Hepatology 2017 Oct;47;1093-1101 — 2017 Oct — 1093-1101